Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Sachets containing 800 mg/day or 1000 mg/day of active (GT-02287), depending on the participant's body weight. Each daily dose will be prepared as an oral suspension by mixing the content of 1 sachet with the vehicle (supplied in an amber glass bottle) and the requisite volume of tap water.”In the company’s words, NCT07280299 on ClinicalTrials.gov
- Tested for
- Parkinson Disease (2 trials)
- Main trialPhase 2
- “The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.”In the company’s words, NCT07280299 on ClinicalTrials.gov
Other drugs for Parkinson Disease
- PembrolizumabMerck & Co. · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Intismeran autogeneMerck & Co. · Moderna · Phase 3
- LenvatinibMerck & Co. · Eisai · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- BHV-8000Biohaven · Phase 2/3
Coming up1
- 30 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 30 Jun 2028 | Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease | |
| Phase 1Recruiting | 30 Nov 2025 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026